Literature DB >> 21712788

Cognitive changes in spinocerebellar ataxia type 2.

Martin Valis1, Jirí Masopust, Jan Bažant, Zuzana Ríhová, Dita Kalnická, Aleš Urban, Alena Zumrová, Jakub Hort.   

Abstract

OBJECTIVES: Cognitive disorders and dementia occur in 19 to 42% of patients with spinocerebellar ataxia type 2 (SCA2). Neuropsychological tests can reveal executive dysfunction, impaired visual and verbal memory, tongue and speech impairment, attention disorders and impaired verbal fluency.
METHODS: We performed psychiatric and neuropsychological examinations in 12 patients diagnosed with genetically confirmed SCA2 and 12 healthy volunteers matching the patients in age, gender, and length of education. The level of motor impairment was determined using the brief ataxia rating scale (BARS). The neuropsychological examination focused on testing executive functions, short-term visual and verbal memory, attention, psychomotor tempo, visual motor coordination, learning ability and comprehension ability. The tests were divided into two subgroups according to the difficulty of motor tasks. The cognitive abilities composite score (CACS) was determined by calculating the arithmetic mean of T scores of the respective tests.
RESULTS: Patients with SCA2 had significantly lower CACSs (p=0.00005) compared to the healthy volunteers. Patients exhibited impaired performance in both difficult and simple motor tests. The severity of cognitive impairment was related to the age at the onset of the disease (p=0.002) but not to the duration or to the overall BARS score.
CONCLUSIONS: Compared to healthy volunteers, patients with SCA2 exhibited significantly worse cognitive performance in all areas tested, including the tests of simple motor tasks. Moreover, the cognitive performance of patients worsened as the difficulty of the motor tasks increased.

Entities:  

Mesh:

Year:  2011        PMID: 21712788

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  6 in total

1.  Cognitive impairments in patients with spinocerebellar ataxia types 1, 2 and 3 are positively correlated to the clinical severity of ataxia symptoms.

Authors:  Jianhua Ma; Chuanjia Wu; Jing Lei; Xiaoning Zhang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Longitudinal study of cognitive and psychiatric functions in spinocerebellar ataxia types 1 and 2.

Authors:  Roberto Fancellu; Dominga Paridi; Chiara Tomasello; Marta Panzeri; Anna Castaldo; Silvia Genitrini; Paola Soliveri; Floriano Girotti
Journal:  J Neurol       Date:  2013-12       Impact factor: 4.849

3.  Brief Ataxia Rating Scale: A Reliable Tool to Rate Ataxia in a Short Timeframe.

Authors:  Sarah Camargos; Francisco Cardoso; Ricardo Maciel; Lucio Huebra; Thiago Roberto Silva; Vilson Geraldo Campos; Rodrigo Alencar
Journal:  Mov Disord Clin Pract       Date:  2016-06-10

4.  Association between spinocerebellar ataxias caused by glutamine expansion and psychiatric and neuropsychological signals - a literature review.

Authors:  Uanda Cristina Almeida-Silva; Jaime Eduardo Cecílio Hallak; Wilson Marques Júnior; Flávia de Lima Osório
Journal:  Am J Neurodegener Dis       Date:  2013-06-21

5.  Non-motor and Extracerebellar Features in Spinocerebellar Ataxia Type 2.

Authors:  José Luiz Pedroso; Pedro Braga-Neto; Marcio Luiz Escorcio-Bezerra; Agessandro Abrahão; Marcus Vinicius Cristino de Albuquerque; Flavio Moura Rezende Filho; Paulo Victor Sgobbi de Souza; Wladimir Bocca Vieira de Rezende Pinto; Franklin Roberto Pereira Borges; Maria Luiza Saraiva-Pereira; Laura Bannach Jardim; Orlando G P Barsottini
Journal:  Cerebellum       Date:  2017-02       Impact factor: 3.847

6.  Social and Cultural Elements Associated with Neurocognitive Dysfunctions in Spinocerebellar Ataxia Type 2 Patients.

Authors:  Roberto Emmanuele Mercadillo; Víctor Galvez; Rosalinda Díaz; Lorena Paredes; Javier Velázquez-Moctezuma; Carlos R Hernandez-Castillo; Juan Fernandez-Ruiz
Journal:  Front Psychiatry       Date:  2015-06-10       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.